EGFR and paronychia: Cytotoxic anticancer agents and multikinase inhibitors (e.g., capecitabine, taxane, and regorafenib) may cause paronychia in addition to HFS; therefore, the frequency can be increased in regimens that involve the use of EGFR inhibitors with cytotoxic anticancer agents.